enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
2.000
+0.050 (2.56%)
At close: Sep 30, 2026, 4:00 PM EDT
1.890
-0.110 (-5.50%)
Pre-market: Oct 1, 2026, 4:11 AM EDT
enGene Therapeutics Employees
As of October 31, 2025, enGene Therapeutics had 82 total employees, including 81 full-time and 1 part-time employees. The number of employees increased by 25 or 43.86% compared to the previous year.
Employees
82
Change (1Y)
25
Growth (1Y)
43.86%
Revenue / Employee
n/a
Profits / Employee
-$1,589,756
Market Cap
134.03M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 82 | 25 | 43.86% | 81 | 1 |
| Oct 31, 2024 | 57 | 24 | 72.73% | 56 | 1 |
| Oct 31, 2023 | 33 | - | - | 31 | 2 |
| Jul 31, 2023 | 33 | - | - | 33 | 0 |
| Apr 30, 2023 | 33 | - | - | 30 | 3 |
Related Stocks
Employee RankingsENGN News
- 15 days ago - enGene Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 15 days ago - enGene Therapeutics Slides: Corporate presentation - Filings
- 16 days ago - enGene Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 22 days ago - enGene Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 22 days ago - enGene Reports Third Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 22 days ago - enGene Therapeutics Earnings release: Q3 2026 - Filings
- 22 days ago - enGene Therapeutics Quarterly report: Q3 2026 - Filings
- 4 weeks ago - enGene to Participate in Upcoming Investor Conferences - Business Wire